Metformin upregulates hENT1 expression and enhances gemcitabine efficacy in pancreatic cancer cells

被引：2
|
作者：
Joseph, Stancy J. [1 ]
Osborne, Taylor [1 ]
Word, Beverly [1 ]
Lyn-Cook, Beverly [1 ]
机构：
[1] US FDA, NCTR, Jefferson, AR USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-4436
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4436
引用
收藏
页数：1
相关论文
共 50 条
  • [31] hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
    Wei Wang
    Xinzhe Yu
    Hengchao Li
    Chuanxin Yang
    Chen Jin
    Xinyu Huang
    BMC Gastroenterology, 23
  • [32] Piperlongumine enhances the efficacy of gemcitabine in pancreatic cancer cells in vitro and in vivo
    Mohammad, Jiyan
    Dhillon, Harsharan
    Reindl, Katie
    CANCER RESEARCH, 2016, 76
  • [33] Human Equilibrative Nucleoside Transporter 1 (hENT1) Predicts the Asian Patient Response to Gemcitabine-Based Chemotherapy in Pancreatic Cancer
    Xiao, Jian-Chun
    Zhang, Tai-Ping
    Zhao, Yu-Pei
    HEPATO-GASTROENTEROLOGY, 2013, 60 (122) : 258 - 262
  • [34] Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
    Bird, N. T. E.
    Elmasry, M.
    Jones, R.
    Psarelli, E.
    Dodd, J.
    Malik, H.
    Greenhalf, W.
    Kitteringham, N.
    Ghaneh, P.
    Neoptolemos, J. P.
    Palmer, D.
    BRITISH JOURNAL OF SURGERY, 2017, 104 (04) : 328 - 336
  • [35] High hENT1 Expression is Predictive of Response of to Adjuvant Gemcitabine for Pancreatic Ductal Adenocarcinoma Patients Randomized to Adjuvant Therapies in the ESPAC Trials
    Neoptolemos, J. P.
    Cox, T. F.
    Greenhalf, W.
    Garner, L.
    Campbell, F.
    Ghaneh, P.
    Palmer, D.
    Mackey, J.
    Dervenis, C.
    Scarpa, A.
    Bassi, C.
    Buechler, M. W.
    PANCREAS, 2012, 41 (08) : 1390 - 1390
  • [36] Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
    Elebro, Jacob
    Ben Dror, Liv
    Heby, Margareta
    Nodin, Bjorn
    Jirstrom, Karin
    Eberhard, Jakob
    ACTA ONCOLOGICA, 2016, 55 (03) : 286 - 296
  • [37] hENT-1 Expression in Circulating Tumor Cells is a Potential Predictive Biomarker of Gemcitabine Outcome in Pancreatic Cancer Patients
    Ma, Y. S.
    Zhao, X. D.
    Tian, X. D.
    Yang, Y. M.
    PANCREAS, 2019, 48 (10) : 1483 - 1484
  • [38] Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression.
    Marechal, R.
    Bachet, J.
    Mackey, J. R.
    Demetter, P.
    Graham, K.
    Couvelard, A.
    Svrcek, M.
    Bardier, A.
    Hammel, P.
    Sauvanet, A.
    Louvet, C.
    Paye, F.
    Rougier, P.
    Hannoun, L.
    Andre, T.
    Dumontet, C. M.
    Cass, C. E.
    Salmon, I.
    Emile, J.
    Van Laethem, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Development of a rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma
    Raponi, M.
    Isaacson, J.
    Ranger-Moore, J.
    Clements, J.
    Richardson, B.
    Ormanns, S.
    Winter, K.
    Allen, A.
    Andersson, R.
    Heinemann, V.
    Dicker, A. P.
    VIRCHOWS ARCHIV, 2012, 461 : S12 - S12
  • [40] Insulin Enhances the Sensitivity of Pancreatic Cancer to Gemcitabine by Regulating NF-κB/hENT-1 Pathway
    Yin, L.
    Peng, Y.
    Lu, Z.
    Wei, J.
    Fu, Y.
    Guo, S.
    Zhu, X.
    Liu, X.
    Zhu, Y.
    Zhang, J.
    Miao, Y.
    PANCREAS, 2017, 46 (10) : 1445 - 1445
12345